Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Neoadjuvant Therapy
Clinical trial register · China

Neoadjuvant Therapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 15 Shanghai 14 Hangzhou 10 Guangzhou 9 Nanjing 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University7 Sun Yat-sen University6 Second Affiliated Hospital, Zhejiang University, School of Medicine5 Peking University People's Hospital4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology3
Site location
Beijing15 Shanghai14 Hangzhou10 Guangzhou9 Nanjing6
All 23 locations
Target enrolment
to

Neoadjuvant Therapy trials in China

76 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
NCT06990178Esophageal Carcinoma, Neoadjuvant Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Not applicable
43
Shenzhen
2028-03-01
Not yet open
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
NCT07720921Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Peking University First Hospital
Phase 2
20
Beijing
2026-11-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
81
Nanjing
2026-09-30
Not yet open
Hubei Cancer Hospital
Phase 2
29
Wuhan
2026-09-21
Recruiting
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2026-09-03
Not yet open
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
NCT07766889Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
DrugsPucotenlimab·Becotatug Vedotin
Sun Yat-sen University
Phase 2
32
Guangzhou
2026-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
45
Hangzhou
2026-08-17
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
NCT07894458Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Not applicable
100
Beijing
2026-08-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
49
Hangzhou
2026-06-03
Recruiting
Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
NCT07695259Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy
DrugsTrastuzumab and Pertuzumab·Olaparib
Wen-Ming Cao
Phase 4
45
Hangzhou
2026-05-25
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Nimotuzumab·Tislelizumab·Docetaxel
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-14
Recruiting
Fudan University
Not applicable
66
Shanghai
2026-03-25
Recruiting
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07787273Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab
DrugsInterferon·Camrelizumab
Hefei Cancer Hospital of the Chinese Academy of Sciences
Phase 2
84
Hefei
2026-03-20
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
DrugsFulzerasib·Sintilimab
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
DrugsBevacizumab biosimilar·Sintilimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Recruiting
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Not yet open
Jinling Hospital, China
Phase 2
30
Nanjing
2025-11-30
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
DrugLenvatinib
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Not yet open
Yantai Yuhuangding Hospital
Phase 2
52
Yantai
2025-10-30
Not yet open
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
NCT07132008Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
DrugsXeloda·Tislelizumab·Capecitabine·Oxaliplatin
First Affiliated Hospital of Guangxi Medical University
Phase 3
94
Nanning
2025-10-01
Not yet open
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
The Affiliated Hospital of Qingdao University
Not applicable
90
Qingdao
2025-09-20
Not yet open
Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
NCT07169864Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neoadjuvant Therapy
Jinsong Lu
Not applicable
44
Shanghai
2025-09-15
Recruiting
Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT07135856Lung Cancer, Neoadjuvant Therapy
Shanghai Chest Hospital
Observational
400
Shanghai
2025-09-01
Recruiting
Fudan University
Phase 2
138
Shanghai
2025-08-28
Not yet open
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
NCT07142863Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
23
Shanghai
2025-08-25
Active, closed
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
NCT07492225Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
Changhai Hospital
Phase 2
120
Shanghai
2025-08-15
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
NCT07386158Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
21
Guangzhou
2025-07-10
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
DrugsNab-paclitaxel·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
DrugsPD-1 inhibitior·Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
DrugsVenetocalx·Ivonescimab
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Not yet open
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
NCT06848439Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
Jiangsu Cancer Institute & Hospital
Phase 2
26
Nanjing
2025-06-15
Active, closed
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Peking University People's Hospital
Observational
200
Beijing
2025-06-03
Recruiting
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06949033Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
DrugPerioperative SOX
Zuoyi Jiao
Phase 3
668
Lanzhou
2025-05-15
Recruiting
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
NCT06904677Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
400
Beijing
2025-05-01
Recruiting
Sun Jing
Phase 2
30
Nanjing
2025-04-20
Recruiting
Zuoyi Jiao
Phase 3
682
Lanzhou
2025-04-15
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
DrugFamitinib
Fudan University
Phase 3
404
Shanghai
2025-04-08
Not yet open
Zhejiang University
Phase 2
20
Hangzhou
2025-03-01
Not yet open
Fujian Medical University Union Hospital
Phase 4
30
Fuzhou
2025-02-01
Recruiting
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
NCT06613165Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
Xijing Hospital
Observational
100
Xi'an
2025-01-01
Active, closed
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer
NCT06868758HER2 Positive Breast Carcinoma, Neoadjuvant Therapy
Chongqing General Hospital
Observational
50
Chongqing
2025-01-01
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Active, closed
Fujian Medical University Union Hospital
Not applicable
175
Fuzhou
2024-12-09
Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT06832904HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
First Affiliated Hospital of Zhejiang University
Phase 2
33
Hangzhou
2024-12-03
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Hubei
2024-10-16
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
DrugsAlbumin-Bound Paclitaxel·Carboplatin
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
Army Medical Center of PLA
Phase 2/3
266
Chongqing
2024-03-08
Recruiting
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Active, closed
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NCT06124378Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
DrugsXeloda·Tislelizumab·Capecitabine·Oxaliplatin
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2023-11-13
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugCetuximab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
181
Beijing
2023-09-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
DrugCamrelizumab
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2022-12-01
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
DrugsKeytruda·Pembrolizumab
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Active, closed
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
NCT05459415Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
54
Wuhan
2022-06-22
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
48
Guangzhou
2021-07-13
Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
NCT04743102Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
Beijing Chao Yang Hospital
Not applicable
260
Beijing
2021-01-01
Active, closed
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
NCT04947241Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugsGemcitabine·Cisplatin
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 1
20
Zhuhai
2020-12-15
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
42
Hangzhou
2020-11-23
Recruiting
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
DrugsRezvilutamide·Apalutamide·Abiraterone acetate·Enzalutamide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
900
Nanjing
2020-02-01
Active, closed
MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer
NCT07875244Breast Cancer, Neoadjuvant Therapy, Axilla; Breast
Fudan University
Not applicable
1,024
Shanghai
2019-06-27
Recruiting
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
NCT03926338Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
DrugsNeoadjuvant toripalimab·Toripalimab
Sun Yat-sen University
Phase 2
270
Guangzhou
2019-05-10
Rows per page Showing 1–76 of 76
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/neoadjuvant-therapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 76 of those studies listing the condition Neoadjuvant Therapy.

How many Neoadjuvant Therapy trials are recruiting in China?

42 of the 76 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 18 have not yet opened recruitment, 14 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Neoadjuvant Therapy), 76 studies
PhaseStudiesRecruitingShare
Phase 2462460.5%
Not applicable9311.8%
Observational9811.8%
Phase 3657.9%
Phase 2/3212.6%
Phase 4212.6%
Phase 1101.3%
Phase 1/2101.3%

Most active sponsors

Lead sponsors with the most studies (Neoadjuvant Therapy)
Lead sponsorStudiesRecruiting
Fudan University74
Sun Yat-sen University65
Second Affiliated Hospital, Zhejiang University, School of Medicine52
Peking University People's Hospital44
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology31
First Affiliated Hospital of Guangxi Medical University20
Fujian Medical University Union Hospital20
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine21
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.